NBTX
Nanobiotix S.A.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-18.84
P/S
230.94
EV/EBITDA
-31.11
DCF Value
$9.69
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-765.4%
Net Margin
-899.7%
ROE
76.7%
ROA
-114.4%
ROIC
334.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $26.6M | $-5.4M | $-0.11 |
| Q4 2024 | $-20.9M | $-46.3M | $-0.98 |
| FY 2024 | $-11.6M | $-68.1M | $-1.44 |
| Q2 2024 | $9.3M | $-21.9M | $-0.46 |
Analyst Ratings
View AllCompany Info
Sector
Healthcare
Industry
—
Country
FR
Exchange
NASDAQ
Beta
0.61
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.